The content on this site is intended for healthcare professionals only
Dr Omar Nadeem speaks to ecancer about the ImmunoPRISM trial, comparing teclistamab against lenalidomide and dexamethasone for high-risk smouldering myeloma.
He details treatment efficacy, including high complete response rates and MRD negativity, improved progression-free survival, and potential for curative outcomes.
Dr Nadeem also addresses the safety profile of T-cell redirecting therapies, focusing on cytokine release syndrome management, infection risks, and the increasing adoption of bispecific antibodies in community centers.
He also covers trial limitations, patient selection criteria, and future research directions for plasma cell disorders.
Talquetamab plus daratumumab with or without pomalidomide improves PFS in r/r multiple myeloma
The evolving treatment landscape in immune thrombocytopenia
Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma
Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure
Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis
ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation
Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL
Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas
Liso-cel in r/r follicular lymphoma shows durable 3-year responses and favourable long-term safety
